Tiny study probes how COVID shots alter immune cell activity
NCT ID NCT05655351
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed early-phase study looked at how mRNA COVID-19 vaccines (Pfizer or Moderna) affect certain immune cells called monocytes in people of different ages. Researchers measured changes in reactive oxygen species (a type of cell activity) and a blood protein called AngII before and after vaccination. The study included 30 healthy adults split into three age groups: under 30, 30-60, and over 60. The goal was to understand the vaccine's biological effects, not to test its safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA COVID-19 vaccine (Pfizer or Moderna)
What this could lead to
If successful, this could help explain how the vaccine affects immune cells and why responses vary by age.
What could go wrong
This is a very small, early-stage study with only 30 participants. It measures lab markers, not health outcomes, so results may not lead to direct medical changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONAVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes, Hôpital Universitaire Caremeau
Nîmes, France, 30029, France